PRM132 Brand name or generic drugs: A national survey of patient perception and preferences  by Jain, S. et al.
A36 V A L U E  I N  H E A L T H  1 6  ( 2 0 1 3 )  A 1 - A 2 9 8  
  
 
PCS scales implied a 1.02-1.04 RR of hospitalization, a 1.07-1.15 RR of being 
unable to work, and a 1.04-1.06 RR of losing the ability to work. CONCLUSIONS: 
Statistical associations with outcomes such as mortality, hospitalization, and 
work ability can be used as benchmarks to interpret score differences on the SF-
36.  
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HEALTH UTILITIES INDEX®: EXTENDING THE AGE RANGE TO PRE-SCHOOLERS  
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OBJECTIVES: To map levels of the Health Status Classification System – 
Preschool (HSCS-PS) into the Health Utilities (HUI) Mark 2 (HUI2) and Mark 3 
(HUI3) measurement systems. This will create a generic utility-based measure of 
health-related quality of life (HRQL) applicable to all persons 2.5 years of age and 
older. METHODS: The existing HSCS-PS is based on the HUI2 and HUI3 (HUI2/3) 
classification systems. The attribute levels of the HSCS-PS were mapped into the 
HUI classification systems attribute levels and, by extension, to the existing HUI 
scoring functions for calculating HRQL utility scores. A questionnaire was 
developed asking participants to map level descriptions between matched HSCS-
PS and HUI2/3 attributes. Mapping questionnaires were completed by 14 health 
care professionals (6 nurses and 8 physicians) responsible for the care of pre-
school aged children diagnosed with cancer or developmental problems. Percent 
exact agreement was calculated among participants for each set of HSCS-PS level 
mappings. Differences in proportions of level mappings within each HSCS-PS 
attribute were tested using Fisher’s exact test. Strength of agreement was 
described as follows: “exact wording assignment” or >70.0% “very strong”; 50.0 to 
69.9% “strong”, 40.0 to 49.9% “moderate”. RESULTS: A total of 41 levels from 10 
attributes of the HSCS-PS were mapped to 19 levels in 5 HUI2 attributes and 33 
levels in 8 HUI3 attributes (total=52). Differences in mapping proportions were 
significant (p<0.001) for all 12 sets of levels. Agreement was very strong for 86.5% 
(n=45), strong for 11.5% (n=6), and moderate for the remaining 2.0% (n=1) of the 
mappings. CONCLUSIONS: There was strong to very strong agreement among 
health care professionals about the overwhelming majority of the mappings of 
HSCS-PS to HUI2/3 attribute levels. Future work will repeat the mapping exercise 
with parents of preschool children in general and clinical populations, and 
include validation studies.  
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OBJECTIVES: Traditional Time trade off (TTO) method was used in EQ-5D social 
valuation protocols, and it has some known problems in the valuation of health 
states considered worse than dead. The aim of our study is to compare two TTO 
variants trying to overcome this issue: lead-time and lag-time TTO. METHODS: 
Quota sampling was undertook in June 2011 in Buenos Aires, as part of the EQ-
5D-5L Multinational Pilot Study. Respondents were randomly assigned to one of 
the TTO variants with two blocks of 5 EQ-5D-5L health states. Tasks were 
administered using a web based digital aid (EQ-VT) administered in a group 
interview. RESULTS: A total of 387 participants were included (mean age 38.85 
[SD: 13.97]; 53.14% females). The mean observed values ranged from 0.44 (0.59) 
for the state 21111 to 0.02 (0.76) for the 53555 in the lead-time group and between 
0.53 (0.52) and 0.08 (0.76) in lag-time group. There were no statistically significant 
differences in the values between TTO variants, except for a significant 
difference of 0.19 for state 33133. In both variants marked peaks were observed 
around the value 0 across all states. We also found evidence of an order effect 
with a greater percentage of responses U=0 in the 5th state valuated compared 
with the first (16.2% to 27.1% in lead-time; 13.71 to 23.32 in lag-time). There were 
no differences regarding process indicators or cognitive debriefing. 
CONCLUSIONS: No important differences were found between TTO variants 
regarding values for EQ-5D-5L health states, which suggest that they could be 
equivalent.  
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EFFECTS OF HEALTH LITERACY ON PATIENTS' ADHERENCE TO  
PRESCRIBED MEDICATIONS: NARRATIVE SYSTEMATIC REVIEW AND  
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OBJECTIVES: Low medication adherence is a serious, but preventable, issue 
facing health care services today. Although health care providers are 
accountable to provide appropriate information to patients regarding their 
medication treatment, patients’ ability to understand the information in the 
process of provider-patient communication has been overlooked. Using a 
systematic literature review and subsequent meta-analysis, this study evaluates 
the impact of health literacy as a predictor of medication adherence among 
patients with chronic diseases. METHODS: Articles were identified through 
literature searches conducted on MEDLINE, PUBMED, CINAHL, PsycInfo, 
International Pharmaceutical Abstracts, Web of Sciences, and review of 
reference citations. Methodological variables, effect sizes of associations, 
diseases, and measures of health literacy and medication adherence were 
abstracted from each eligible article. Studies were categorized by disease 
category, statistical methods and significance (bivariate or multivariate 
significance and insignificance), literacy and adherence outcome metrics. The 
population effect size of the association between health literacy and medication 
adherence are estimated based on simulation based meta-analysis. RESULTS: 
Across 29 studies, 47% multivariate studies and 80% bivariate studies reported 
that higher health literacy levels were statistically significantly associated with 
better adherence to prescribed medications. There was wide variation on the 
association between health literacy and medication adherence across diseases. 
For example, 75% of studies on diabetes reported no statistical associations 
between health literacy and medication adherence, while 100% of studies on 
glaucoma reported statistical associations. The Monte Carlo simulation based 
meta-analysis found that a statistically significant association between health 
literacy and medication adherence (p<0.001), although the unweighted 
population effect size is relatively small (r=0.122 with a 95% confidence interval 
of (0.0849, 0.159). CONCLUSIONS: Health literacy is a proven predictor of 
medication adherence, and it is more potent in some diseases than others. 
Adherence intervention may focus on patients’ health literacy in the provider-
patient communications and health information exchange.  
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OBJECTIVES: This study evaluated the psychometric properties of the FACIT-
Fatigue patient-reported outcome (PRO) instrument (Yellen et al., 1997) in 
patients with iron deficiency anemia (IDA). METHODS: As part of a randomized, 
controlled clinical trial IDA patients (n=808) completed the FACIT-Fatigue, Linear 
Analogue Scale Assessments (LASAs), and Medical Outcomes Study Short-Form 
36 (SF-36) PRO instruments at five weekly visits. Baseline and Week 3 data, 
including hemoglobin, were used to validate the FACIT-Fatigue scale in this IDA 
patient population. RESULTS: The FACIT-Fatigue showed little to no ceiling or 
floor effects and produced reasonable response variability across items. Further, 
test-retest reliability (ICC=.87) and internal consistency reliability (Baseline α=.93) 
were both acceptable. Hypothesized convergent validity associations between 
other PROs and the fatigue scale were largely supported, although the 
hemoglobin-fatigue association was not as strong as expected (Baseline r =0.04; 
ns, Week 3 r=0.15; p<0.001). As predicted, known-groups validity showed that 
patients receiving intravenous iron treatment with ferumoxytol reported less 
fatigue than their placebo-treated counterparts (p<0.001). Further, a series of t-
tests showed that patients with severely low hemoglobin levels reported 
significantly greater fatigue than those with mild, moderate, and severe values 
(ps<0.05). Finally, the FACIT-Fatigue demonstrated ability to detect change using 
the SF-36 Vitality domain as a PRO anchor. Specifically, patients with worsened 
vitality reported worsened fatigue (ns), whereas patients grouped according to 
much, moderate, and minimal vitality improvements reported fatigue 
improvements (all ps<0.001; effect sizes increasing across groups accordingly). 
CONCLUSIONS: This study demonstrated that the FACIT-Fatigue provides a 
psychometrically valid assessment of fatigue in patients with IDA. Specifically, 
the scale was reproducible and internally consistent in an IDA population and 
exhibited construct validity in terms of predicted convergent/discriminant 
correlations and across known groups. Finally, the FACIT-Fatigue was able to 
detect change when change occurred in a PRO anchor.  
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OBJECTIVES: Previous Rasch analysis on the National Eye Institute Visual 
Function Questionnaire (NEI VFQ-25) has suggested that a modified instrument 
may provide improved coverage and targeting of patient-reported visual function 
for patients with eye diseases. The aims of this study were to propose a Rasch-
based scoring structure, the NEI VFQ-25-R, and to assess its psychometric 
performance. METHODS: The NEI VFQ-25-R was developed by combining 
response levels for disordered thresholds for 15 NEI VFQ-25 items, excluding four 
poorly fitting items and including six optional near and distance subscale items. 
NEI VFQ-25-R items were regrouped into two subscales, Activity Limitation and 
Socio-Emotional Impact, based on literature, item face validity and clinician 
input. Performance was evaluated using Rasch analysis by assessing item fit 
validity, threshold targeting, item dependency, and reliability using pooled 
baseline data (2487 person measurements) from six clinical trials across four 
retinal diseases. RESULTS: No disordered thresholds were observed for any NEI 
VFQ-25-R items, and only three misfitting items were reported. The estimated 
Person Separation Index was 0.94, suggesting good reliability. Only two items 
had a residual correlation >0.30, demonstrating minimal local dependency 
between items. Distribution of item thresholds revealed a reduced ceiling effect 
compared with the NEI VFQ-25. Threshold targeting was better for patients with 
neovascular age-related macular degeneration, lower visual acuity, and low 
reported visual function. CONCLUSIONS: Collapsing disordered response 
categories and excluding misfitting items improved psychometric performance 
for the NEI VFQ-25-R compared with the NEI VFQ-25. The reduced ceiling effect 
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may reflect more effective population targeting and improved instrument 
coverage. Additional research will determine whether the two subscale structure 
of the NEI VFQ-25-R provides better interpretability of potential differences in 
patient-reported visual functioning than the NEI VFQ-25.  
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OBJECTIVES: This study aimed to assess the patient perception about brand 
name and generic drugs and to identify clusters with different preferences, and 
to evaluate the willingness to pay for a brand-name drug over a generic 
alternative. METHODS: A cross-sectional survey was conducted through self-
administered, online questionnaire. The questionnaire comprised 27 items, 
which included several attributes of pharmaceutical products like therapeutic 
efficacy, brand, price and source of information. Questionnaire also included 4 
hypothetical scenarios to ask about patients’ preferences to purchase brand-
name drugs over generic drugs and vice versa. Descriptive statistics were used to 
examine characteristics of the participants and to summarize our results. 
Preference clusters were identified, individual level utility functions were 
estimated and the willingness to pay for a brand name drug over a generic 
alternative. RESULTS: The usable response rate was 68%. The mean age of the 
respondents was approximately 29 years (range 18-68 years). Most respondents 
believed that generic drugs were less expensive (91.8%) and therapeutically 
effective (72.2%) than brand-name drugs, but only 52.2% preferred to take generic 
drugs themselves. Four clusters with distinctive individual level preferences with 
some differences in socioeconomic background were identified. About half of the 
respondents were price sensitive. Approximately 62% of the respondents were 
willing to take brand-name drugs for chronic diseases such as cardiovascular 
and respiratory diseases. 74% respondents preferred to purchase over the 
counter generic drugs for general ailments such as headache, sore throat and 
fever. Few respondents had preferences such as specific brand or to have a 
pharmacist or a physician as an information source for buying over the counter 
drugs. CONCLUSIONS: These findings provided new information on the 
consequent effects of price, efficacy, counseling, brand and other product 
characteristics on the choice by patients between branded and generic drug.  
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OBJECTIVES: Initial medication adherence, filling pharmacy scripts when first 
prescribed to begin a regimen, is an important yet understudied area. Long-term 
outcomes for chronically ill patients are dependent upon this critical early 
treatment phase. Recognizing how research findings can inform subsequent 
translation into effective clinical practices, this study summarizes the current 
literature on behavioral and psychosocial risk factors affecting initial medication 
adherence. METHODS: An international working group conducted a 
comprehensive systematic review utilizing multiple search terms for patient, 
provider or organizational factors associated with initial adherence. Following 
rigorous efforts limiting inclusion to studies targeting initial adherence versus 
broader or more ambiguous early treatment periods, we reviewed publications 
presenting primary data from 1966-2012. Eligible articles were abstracted 
documenting terminology, methodological approaches, and factors associated 
with adherence problems. We noted the frequency that unique risk factors were 
analyzed and their relative effect sizes calculated by the study authors. 
RESULTS: Only 24 publications met eligibility criteria from 865 potentially 
relevant publications. The diverse papers covered an array of study designs, 
anaytic techniques, and populations (7 countries, sample sizes 60–5.2 million), 
utilizing administrative datasets and self-reported surveys. Several articles 
modelled numerous risk factors yet others focused on single variables. The most 
prevalent factor (n=16) was specific medication or drug class (OR range  
1.50–4.87), followed by 14 papers reporting comorbodities or illness severity (ORs 
1.40–2.78); 11 articles noted medication cost effects (ORs 1.20–7.30). Less 
frequently cited were socioeconomic status, physician characteristics or 
medication beliefs, factors magnifying adherence problems up to six-times. 
CONCLUSIONS: Attention to critical influences upon adherence during the initial 
treatment course is imperative to improving outcomes. Evolving research efforts 
into associations between initial adherence and numerous risk factors can 
highlight contributions towards beneficial interventions. Multidisciplinary 
approaches, particularly those tailored to specific risks and patient preferences, 
may help reconcile potential barriers while establishing positive longitudinal 
medication behavior.  
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OBJECTIVES: The time trade-off (TTO) and the standard gamble (SG) are 
instruments that can be administered to patients in the direct elicitation of 
health utilities (HU). A previous systematic review of the literature (56 relevant 
publications, 79 study arms and 26 disease categories) indicated significant 
overall correlation in patient-elicited HU between TTO and SG. The present 
analysis further examined the correlation between TTO and SG within specific 
subgroups from the previous analysis. METHODS: Correlation between mean or 
median TTO and SG was explored by Spearman’s rank correlation test, when a 
sufficient number of study arms were available, for the following subgroups: 
incremental HU, disease, gender, age, income, education level and employment 
status. All comparisons were undertaken by sorting the mean or median HU 
values according to TTO, in increasing order by increments of 0.10. RESULTS: For 
the incremental analysis of mean TTO versus SG, significant positive correlation 
was observed when HU values were greater than 0.6 (r=0.687), 0.7 (r=0.478) and 
0.8 (r=0.525) or lower than 0.7 (r=0.564); no significant correlation was observed 
for HU values lower than 0.6 (r=0.7 with post-hoc analyses identifying the 
scarcity of studies as a plausible reason) or greater than 0.9 (r= -0.037). Overall 
mean SG was greater than overall mean TTO for all disease subgroups except 
HIV, with significant positive correlations observed in two diseases: 
cardiovascular disease (r=0.929) and ocular disease (r=0.504). Significant positive 
correlation was observed in both subgroups of females (r=0.814) and males 
(r=0.738). The series of subgroup analyses pertaining to median incremental HU 
values yielded findings similar to those in the analysis of means. CONCLUSIONS: 
The correlation between patient-reported TTO and SG outcomes was observed 
for numerous demographic and analytical subgroups. The occurrence of 
correlation may be more widespread than observed, given the limitations 
imposed by the existing study arm sample.  
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OBJECTIVES: Work disability is known to seriously impair individual quality of 
life and to cause considerable societal costs, primarily due to medical treatment 
and vocational rehabilitation. Following the WHO model of “disease - functional 
limitation - work disability”, we analyzed the longitudinal effects of perceived 
current health and functional limitations on future work disability. METHODS: In 
2007, two adult sub-samples of the Kantar Health European Healthcare Panel in 
Germany and UK were surveyed (n=4.008), and self-reports about perceived 
health status (SF-12), 24 different disease conditions and occupational status 
were collected. In 2012 the participants were re-contacted and completed a 
health status and work disability questionnaire. Careful panel management and 
quota adjustment ensured the representativeness of the samples for the 
populations in the countries. RESULTS: In 2007, 48.1% of the sample was full-
time (GER: 57.4%; UK: 38.9%) and 12.5% part-time (GER: 10.6%; UK: 14.5%) 
employed. Five years later, in 2012, 19% of the previously full- or part-time 
employed individuals were no longer employed due to health reasons. Health 
related unemployment in 2012 was highly correlated with general health status 
(gamma: 0.70; p<0.01) and functional limitations as measured by the SF-12 
subscale in 2007(=0.39; p>0.01). Of those still employed in 2012, 16.2% were 
impaired in their jobs. Most frequently they had to take breaks more often (7.5%), 
were restricted in performing typical elements of work (6.1%) or required special 
tools (2.7%). CONCLUSIONS: Future amount and nature of work disability of a 
workforce can be predicted by using conventional measures of perceived health 
and functional status. The potential use of prognostic considerations to assess 
the need for preventive and rehabilitative measures will be discussed.  
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OBJECTIVES: The PPIUS is a single-item patient-reported rating scale capturing 
degree of urgency associated with micturition and/or incontinence. We 
evaluated its measurement properties in patients with lower urinary tract 
symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). METHODS: 
Subjects enrolled in a Phase II, randomized, double-blind, 12-week study of fixed 
dose combinations of solifenacin with tamsulosin in an Oral Control 
Administration System (OCASTM) formulation TOCAS monotherapy, and placebo 
completed several disease specific patient reported outcomes and rated their 
level of urgency at every micturition and number of incontinence episode using 
the PPIUS prior to visits 2 (baseline), 3, 4, and 6 (end of study [EOS]). Six different 
scores were derived from the PPIUS including the mean, maximum, Total 
Urgency and Frequency Score (TUFS)* (defined as average sum of urgency 
episodes during a 24 hour period), number of urgency episodes, number of 
severe urgency episodes, and number of urge incontinence episodes. 
Measurement properties, including reliability, validity and responsiveness, were 
assessed. RESULTS: 1,010 males (mean age: 66) were enrolled. Intra class 
correlations (test-retest reliability) exceeded 0.70 for all scores. All PPIUS scores 
at Visit 2 and EOS were significantly (p<0.001) different for those above/below the 
median on International Prostate Symptom Score (IPSS) storage scores, but TUFS 
and number of urgency episodes had highest partial eta-squared values 
indicating these scores demonstrated the greatest ability to discriminate 
between groups differing in baseline severity (known groups validity). Three 
PPIUS scores (maximum, TUFS and urgency episodes) showed notably higher 
